ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Nov. 03, 2026 (GLOBE NEWSWIRE) —…
Category: Globenewswire
Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion
COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION OF BXCL-501 Q3 2026 revenues of $4.4 billion, a decrease…
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”),…
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company…
Kura Oncology to Report Third Quarter Financial Results on November 10
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines…
ANI Pharmaceuticals to Present at Upcoming November Investor Conferences
PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that…
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2026 sowie Informationen zur Geschäftsentwicklung
Erstmals globale Daten für einen bispezifischen PD-(L)1xVEGF-Immunmodulatorkandidaten in Kombination mit einem Antikörper-Wirkstoff-Konjugat-Kandidat bei Lungenkrebs vorgestellt: Pumitamig in Kombination mit Elfetabart…
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung…
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines…
Transactions in connection with share buy-back program
Company announcement no. 44 – 2603 November 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG…